Life4me+ news story
At CROI 2026, investigators presented preliminary data from the RIO trial suggesting that exposure to broadly neutralizing antibodies may alter viral rebound dynamics following treatment interruption in a subset of individuals living with HIV.
The findings do not represent a cure, nor do they support treatment interruption outside clinical trials. However, they provide early evidence that immune-based interventions might modulate post-treatment viral control.
The results presented reflect only part of the ongoing study, and several mechanistic analyses remain in progress.
The RIO trial evaluates two long-acting broadly neutralizing antibodies — 3BNC117-LS and 10-1074-LS — administered to individuals who initiated antiretroviral therapy early after infection and maintained sustained viral suppression.
Read the full news story here.
View all Life4me+ reports from CROI 2026
SEE ALSO:
View all aidsmap reports from CROI 2026
Source : Life4me+
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.